Advertisement
New Zealand markets close in 4 hours 29 minutes
  • NZX 50

    11,861.63
    +58.35 (+0.49%)
     
  • NZD/USD

    0.5943
    +0.0009 (+0.15%)
     
  • NZD/EUR

    0.5547
    +0.0006 (+0.11%)
     
  • ALL ORDS

    7,967.50
    +29.60 (+0.37%)
     
  • ASX 200

    7,714.20
    +30.70 (+0.40%)
     
  • OIL

    83.43
    +0.07 (+0.08%)
     
  • GOLD

    2,336.10
    -6.00 (-0.26%)
     
  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     
  • DAX

    18,137.65
    +276.85 (+1.55%)
     
  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     
  • NIKKEI 225

    38,105.01
    +552.85 (+1.47%)
     
  • NZD/JPY

    91.8980
    +0.1320 (+0.14%)
     

Analyzing Novartis’s Revenue in Q1

Analyzing Novartis’s Revenue in Q1

In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.